Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given an average rating of “Buy” by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.48.

AUPH has been the topic of several research analyst reports. Cantor Fitzgerald set a $16.00 price objective on Aurinia Pharmaceuticals and gave the stock an “overweight” rating in a research note on Thursday, March 15th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 5th. BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 14th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, May 2nd.

Several hedge funds and other institutional investors have recently modified their holdings of AUPH. BlackRock Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $3,261,000. Franklin Resources Inc. raised its stake in shares of Aurinia Pharmaceuticals by 33.2% during the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after purchasing an additional 414,400 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aurinia Pharmaceuticals by 36.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after purchasing an additional 319,639 shares in the last quarter. Swiss National Bank bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $421,000. Finally, Spark Investment Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $153,000. Institutional investors and hedge funds own 25.77% of the company’s stock.

Shares of AUPH stock traded up $0.03 during mid-day trading on Friday, reaching $5.71. 172,297 shares of the company were exchanged, compared to its average volume of 661,277. Aurinia Pharmaceuticals has a fifty-two week low of $4.41 and a fifty-two week high of $7.68. The company has a market capitalization of $482.37 million, a P/E ratio of -6.11 and a beta of 2.28.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 20.67% and a negative net margin of 8,193.08%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. research analysts forecast that Aurinia Pharmaceuticals will post -0.7 EPS for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.